$23.18
-0.75-3.13%
At Close: -
$23.18
00.00%
After Hours: Jul 19, 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Veracyte
VCYTNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Veracyte (NASDAQ:VCYT) Stock, Analyst Ratings, Price Targets, Forecasts
Veracyte Inc has a consensus price target of $31.43 based on the ratings of 8 analysts. The high is $42 issued by Morgan Stanley on July 30, 2021. The low is $21 issued by Morgan Stanley on February 26, 2024. The 3 most-recent analyst ratings were released by Needham, Goldman Sachs, and Morgan Stanley on May 8, 2024, April 15, 2024, and February 26, 2024, respectively. With an average price target of $25.33 between Needham, Goldman Sachs, and Morgan Stanley, there's an implied 9.29% upside for Veracyte Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Goldman Sachs
Morgan Stanley
Stephens & Co.
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Veracyte
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 16.48% | Needham | Mike Matson | $33 → $27 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | 20.79% | Goldman Sachs | Matthew Sykes | $32 → $28 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | -9.4% | Morgan Stanley | Tejas Savant | $22 → $21 | Maintains | Underweight | Get Alert |
| 02/23/2024 | Buy Now | 42.36% | Needham | Mike Matson | $30 → $33 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | -5.09% | Morgan Stanley | Tejas Savant | $23 → $22 | Maintains | Underweight | Get Alert |
| 11/08/2023 | Buy Now | 29.42% | Needham | Mike Matson | $35 → $30 | Maintains | Buy | Get Alert |
| 10/23/2023 | Buy Now | 38.05% | Goldman Sachs | Matthew Sykes | $37 → $32 | Maintains | Buy | Get Alert |
| 10/20/2023 | Buy Now | 38.05% | Goldman Sachs | Matthew Sykes | $37 → $32 | Maintains | Buy | Get Alert |
| 10/10/2023 | Buy Now | 46.68% | Stephens & Co. | Mason Carrico | → $34 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | -0.78% | Morgan Stanley | Tejas Savant | $22 → $23 | Maintains | Underweight | Get Alert |
| 08/09/2023 | Buy Now | 50.99% | Needham | Mike Matson | $34 → $35 | Maintains | Buy | Get Alert |
| 05/08/2023 | Buy Now | 29.42% | Stephens & Co. | Mason Carrico | → $30 | Reiterates | → Overweight | Get Alert |
| 02/23/2023 | Buy Now | 46.68% | Needham | Mike Matson | $33 → $34 | Maintains | Buy | Get Alert |
| 01/18/2023 | Buy Now | — | Raymond James | Andrew Cooper | — | Downgrade | Outperform → Market Perform | Get Alert |
| 01/05/2023 | Buy Now | 42.36% | Scotiabank | Sung Ji Nam | → $33 | Initiates | → Sector Outperform | Get Alert |
| 11/04/2022 | Buy Now | -5.09% | Morgan Stanley | Tejas Savant | $23 → $22 | Maintains | Underweight | Get Alert |
| 11/04/2022 | Buy Now | 16.48% | Raymond James | Andrew Cooper | $31 → $27 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 42.36% | Needham | Mike Matson | $31 → $33 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 50.99% | SVB Leerink | Puneet Souda | $30 → $35 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 33.74% | Raymond James | Andrew Cooper | $30 → $31 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 33.74% | Needham | Mike Matson | $26 → $31 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 29.42% | Stephens & Co. | Mason Carrico | $44 → $30 | Maintains | Overweight | Get Alert |
| 05/04/2022 | Buy Now | -0.78% | Morgan Stanley | Tejas Savant | $25 → $23 | Maintains | Underweight | Get Alert |
| 05/04/2022 | Buy Now | 29.42% | Raymond James | Andrew Cooper | $34 → $30 | Maintains | Outperform | Get Alert |
| 05/04/2022 | Buy Now | 12.17% | Needham | Mike Matson | $31 → $26 | Maintains | Buy | Get Alert |
| 03/15/2022 | Buy Now | 33.74% | Needham | Mike Matson | $35 → $31 | Maintains | Buy | Get Alert |
| 03/02/2022 | Buy Now | 89.82% | Stephens & Co. | Mason Carrico | $52 → $44 | Maintains | Overweight | Get Alert |
| 03/01/2022 | Buy Now | 46.68% | Raymond James | Andrew Cooper | $62 → $34 | Maintains | Outperform | Get Alert |
| 03/01/2022 | Buy Now | 72.56% | SVB Leerink | Puneet Souda | $45 → $40 | Maintains | Outperform | Get Alert |
| 01/07/2022 | Buy Now | 124.33% | Stephens & Co. | Mason Carrico | → $52 | Initiates | → Overweight | Get Alert |
| 11/10/2021 | Buy Now | 167.47% | Raymond James | Andrew Cooper | — | Maintains | Outperform | Get Alert |
| 07/30/2021 | Buy Now | 81.19% | Morgan Stanley | — | — | Maintains | Underweight | Get Alert |
| 07/30/2021 | Buy Now | 137.27% | Needham | Mike Matson | — | Maintains | Buy | Get Alert |
| 07/30/2021 | Buy Now | 158.84% | SVB Leerink | Puneet Souda | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Veracyte (VCYT) stock?
The latest price target for Veracyte (NASDAQ:VCYT) was reported by Needham on May 8, 2024. The analyst firm set a price target for $27.00 expecting VCYT to rise to within 12 months (a possible 16.48% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Veracyte (VCYT)?
The latest analyst rating for Veracyte (NASDAQ:VCYT) was provided by Needham, and Veracyte maintained their buy rating.
When was the last upgrade for Veracyte (VCYT)?
There is no last upgrade for Veracyte
When was the last downgrade for Veracyte (VCYT)?
The last downgrade for Veracyte Inc happened on January 18, 2023 when Raymond James changed their price target from N/A to N/A for Veracyte Inc.
When is the next analyst rating going to be posted or updated for Veracyte (VCYT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Veracyte (VCYT) correct?
While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a maintained with a price target of $33.00 to $27.00. The current price Veracyte (VCYT) is trading at is $23.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.